Sökning: onr:"swepub:oai:DiVA.org:his-15263" >
Plasminogen binding...
Plasminogen binding inhibitors demonstrate unwanted activities on GABAA and glycine receptors in human iPSC derived neurons
-
- Kristensson, Lisbeth (författare)
- AstraZeneca, Mölndal, Sweden
-
- Lundin, Anders (författare)
- Karolinska Institutet,AstraZeneca, Mölndal, Sweden / Karolinska Institutet, Stockholm, Sweden
-
- Gustafsson, David (författare)
- Emeriti Bio, AZ Bioventure Hub, Mölndal, Sweden
-
visa fler...
-
- Fryklund, Jan (författare)
- Emeriti Bio, AZ Bioventure Hub, Mölndal, Sweden
-
- Fex, Tomas (författare)
- Emeriti Bio, AZ Bioventure Hub, Mölndal, Sweden
-
- Delsing, Louise (författare)
- Gothenburg University,Göteborgs universitet,Högskolan i Skövde,Institutionen för biovetenskap,Forskningscentrum för Systembiologi,AstraZeneca, Mölndal, Sweden / the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden,Bioinformatics,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
- Ryberg, Erik (författare)
- AstraZeneca, Mölndal, Sweden
-
visa färre...
-
(creator_code:org_t)
- Elsevier, 2018
- 2018
- Engelska.
-
Ingår i: Neuroscience Letters. - : Elsevier. - 0304-3940 .- 1872-7972. ; 681, s. 37-43
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
https://gup.ub.gu.se...
-
visa färre...
Abstract
Ämnesord
Stäng
- Plasminogen binding inhibitors (PBIs) reduce the risk of bleeding in hemorrhagic conditions. However, generic PBIs are also associated with an increased risk of seizures, an adverse effect linked to unwanted activities towards inhibitory neuronal receptors. Development of novel PBIs serve to remove compounds with such properties, but progress is limited by a lack of higher throughput methods with human translatability. Herein we apply human induced pluripotent stem cell (hiPSC) derived neurons in combination with dynamic mass redistribution (DMR) technology to demonstrate robust and reproducible modulation of both GABAA and glycine receptors. These cells respond to GABA (EC50 0.33 ± 0.18 μM), glycine (EC50 11.0 ± 3.7 μM) and additional ligands in line with previous reports from patch clamp technologies. Additionally, we identify and characterize a competitive antagonistic behavior of the prototype inhibitor and drug tranexamic acid (TXA). Finally, we demonstrate proof of concept for effective counter-screening of lead series compounds towards unwanted GABAAreceptor activities. No activity was observed for a previously identified PBI candidate drug, AZD6564, whereas a discontinued analog, AZ13267257, could be characterized as a potent GABAA receptor agonist.
Ämnesord
- NATURVETENSKAP -- Biologi -- Cellbiologi (hsv//swe)
- NATURAL SCIENCES -- Biological Sciences -- Cell Biology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Nyckelord
- Drug screening
- Dynamic mass redistribution
- GABA(A) receptor
- Glycine receptor
- Pharmacology
- hiPSC derived neurons
- Bioinformatik
- Bioinformatics
- INF502 Biomarkers
- INF502 Biomarkörer
- Drug screening
- Dynamic mass redistribution
- GABAA receptor
- Glycine receptor
- hiPSC derived neurons
- Pharmacology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas